FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation

The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's BTAI BXCL501, to treat agitation associated with dementia.

  • The designation intends to expedite the development and review of certain product candidates.
  • After a routine review of TRANQUILITY study data, a lower 30 mcg dose showed numerical improvements compared to the placebo.
  • Earlier this year, the company announced positive topline data from the Phase 1b/2 TRANQUILITY study.
  • Price Action: BTAI shares gained 8.53% at $51 in premarket on the last check Monday.
Loading...
Loading...
BTAI Logo
BTAIBioXcel Therapeutics Inc
$1.910.53%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
1.53
Growth
N/A
Quality
N/A
Value
25.38
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...